日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial

在老年初治转移性胰腺癌患者中，NALIRIFOX 与白蛋白结合型紫杉醇联合吉西他滨的疗效比较：一项关键性 NAPOLI 3 试验的亚组分析

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.106043
Macarulla, T; Cid, R Pazo; Womack, M S; Gracian, A Cubillo; Zervoudakis, A; Hatoum, H; Chung, V; Patel, A; Paulson, A S; Pant, S; O'Reilly, E M; Hubner, R A; Van Cutsem, E; Bekaii-Saab, T; Zhang, L; Li, J; Chen, H; Maxwell, F; Wainberg, Z A; Melisi, D
胰腺癌
肿瘤
肿瘤免疫
发表日期：2026
文献求助 收藏

Correction: Behavioral HIV-serosurvey reveals clustering of risk factors likely plays a key role in sustaining HIV epidemic in rural KwaZulu- Natal, South Africa

更正：行为艾滋病血清学调查显示，风险因素聚集可能在南非夸祖鲁-纳塔尔省农村地区艾滋病疫情的持续蔓延中发挥关键作用。

期刊:BMC Public Health
影响因子:3.6
doi:10.1186/s12889-026-26405-5
Conan, Nolwenn; Ben-Farhat, Jihane; Ohler, Liesbet; Kenyon, Chris; Van Cutsem, Gilles; Huerga, Helena
发表日期：2026
文献求助 收藏

Heart rate variability during wakefulness reflects sleep apnea indicators but remains context-dependent

清醒状态下的心率变异性可以反映睡眠呼吸暂停的指标，但仍受情境影响。

期刊:Frontiers in Physiology
影响因子:3.4
doi:10.3389/fphys.2026.1793057
Balali, Paniz; Omari, Ghita; Hossein, Amin; Abdessater, Elza; Batonon, Celia; Hagson, Hannes; Wacquier, Benjamin; Varon, Carolina; van den Berg, Nicholas H; Van Cutsem, Jeroen; Van Puyvelde, Martine; Furian, Michael; Verges, Samuel; Maggioni, Martina Anna; Caiani, Enrico Gianluca; Debeir, Olivier; Hein, Matthieu; van de Borne, Philippe; Pattyn, Nathalie; Faoro, Vitalie; Rabineau, Jeremy
发表日期：2026
文献求助 收藏

Menstrual Health in Servicewomen: The Menstrual Cycle, Menstrual Disturbances, and Occupational Consequences

女兵月经健康：月经周期、月经紊乱及其对职业的影响

期刊:Sports Medicine-Open
影响因子:
doi:10.1186/s40798-025-00963-1
Mikkonen, Ritva S; McClung, Holly; Giersch, Gabrielle; Van Cutsem, Jeroen; Wright, Helen; O'Leary, Thomas J; Greeves, Julie P
发表日期：2026
文献求助 收藏

NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

NOTCH1 突变与替利珠单抗治疗晚期或转移性食管鳞状细胞癌的生存分析：来自随机 III 期 RATIONALE-302 试验的生物标志物分析

期刊:Journal of Clinical Oncology
影响因子:41.9
doi:10.1200/JCO-24-01818
Lu Zhihao, Du Wenting, Jiao Xi, Wang Yanni, Shi Jingwen, Shi Yang, Shu Yongqian, Niu Zuoxing, Hara Hiroki, Wu Jun, Hsu Chih-Hung, Van Cutsem Eric, Brock Malcolm V, Zhang Zhang, Ding Ningning, Zhang Yun, Shen Zhirong, Shen Lin
细胞生物学
Notch
发表日期：2025
文献求助 收藏

Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2

接受呋喹替尼联合最佳支持治疗的转移性结直肠癌患者的质量调整生存期：FRESCO-2 研究结果

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.104297
Stintzing, S; Tabernero, J; Satoh, T; Dasari, A; Lonardi, S; Eng, C; Garcia-Carbonero, R; Elez, E; Yoshino, T; Sobrero, A F; Yao, J C; Kasper, S; Arnold, D; Basic, E; Granold, M; Petschulies, M; Wu, L; Chung, Y-C; Chen, L; Yang, Z; Van Cutsem, E
肿瘤
肠癌
肿瘤免疫
发表日期：2025
文献求助 收藏

Health-related quality of life and performance status with NALIRIFOX versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma: results from the NAPOLI 3 trial

在既往未接受过治疗的转移性胰腺导管腺癌患者中，NALIRIFOX方案与白蛋白结合型紫杉醇+吉西他滨方案相比，在健康相关生活质量和体能状态方面的表现：NAPOLI 3试验结果

期刊:ESMO Open
影响因子:8.3
doi:10.1016/j.esmoop.2025.105534
Melisi, D; Macarulla, T; De La Fouchardière, C; Pazo Cid, R A; Chandana, S R; Kiss, I; Lee, W J; Goetze, T O; Van Cutsem, E; Paulson, A S; Bekaii-Saab, T; Pant, S; Hubner, R A; Maxwell, F; Zhang, L; Benzaghou, F; O'Reilly, E M; Wainberg, Z A
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

First-Line Tislelizumab Plus Chemotherapy for Esophageal Squamous Cell Carcinoma with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-306

一线替雷利珠单抗联合化疗治疗程序性死亡配体1表达≥1%的食管鳞状细胞癌：RATIONALE-306研究的回顾性分析

期刊:Advances in Therapy
影响因子:4
doi:10.1007/s12325-025-03115-9
Xu, Jianming; Kato, Ken; Hubner, Richard; Park, Sook Ryun; Kojima, Takashi; Ishihara, Ryu; Wyrwicz, Lucjan; Van Cutsem, Eric; Jimenez-Fonseca, Paula; Wu, Hongqian; Wang, Lei; Yan, Sebastian; Shi, Jingwen; Kadva, Alysha; Yoon, Harry H
细胞生物学
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

A plain language summary of NALIRIFOX compared with nab-paclitaxel and gemcitabine for patients with metastatic pancreatic cancer (NAPOLI 3)

NAPOLI 3 研究比较了 NALIRIFOX 与 nab-紫杉醇和吉西他滨治疗转移性胰腺癌患者的疗效，并总结了以下简明语言结果：

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2458458
Wainberg, Zev A; Melisi, Davide; Macarulla, Teresa; Pazo Cid, Roberto; Chandana, Sreenivasa R; De La Fouchardière, Christelle; Dean, Andrew; Kiss, Igor; Jin Leei, Woo; Goetze, Thorsten O; Van Cutsem, Eric; Paulson, A Scott; Bekaii-Saab, Tanios; Pant, Shubham; Hubner, Richard A; Xiao, Zhimin; Chen, Huanyu; Benzaghou, Fawzi; O'Reilly, Eileen M
胰腺癌
肿瘤
肿瘤免疫
发表日期：2025
文献求助 收藏

Trastuzumab deruxtecan in HER2-positive stomach or gastroesophageal junction cancer: a plain language summary of the DESTINY-Gastric02 study

曲妥珠单抗德鲁替康治疗HER2阳性胃癌或胃食管交界处癌：DESTINY-Gastric02研究的简明摘要

期刊:Future Oncology
影响因子:2.6
doi:10.1080/14796694.2025.2567230
Van Cutsem, Eric
胃癌
肿瘤
肿瘤免疫
HER2
发表日期：2025
文献求助 收藏